MVT: In the News

Salt Lake City, UT –Wednesday November, 5 th  2025— Researchers from the University of Utah and Microvascular Therapeutics (MVT) will be presenting new preclinical data demonstrating that focused ultrasound (FUS) using proprietary phase-shift microbubbles, NanoBlate (MVT-101), can selectively ablate brain tumors and open the blood-brain barrier (BBB) in targeted regions, potentially enabling safer, more precise, and non-invasive treatment for patients with malignant brain tum

Phase‑shift microbubble (also known as nanobubble) technology demonstrates robust thrombus resolution in a porcine deep vein thrombosis (DVT) model. Salt Lake City, UT – Microvascular Therapeutics, Inc. (MVT) today announced the publication of compelling preclinical data demonstrating that its proprietary phase‑shift microbubble platform, MVT‑101 (Solv), significantly enhances sonothrombolysis in a clinically relevant porcine model of deep vein thrombosis (DVT). The study app

Chicago, IL – October 7th, 2025 – Microvascular Therapeutics (MVT), a clinical-stage biopharmaceutical company pioneering innovations in...

Salt Lake City (Utah), September  29, 2025: Microvascular Therapeutics (MVT), the leader in development of next-generation ultrasound...

Nashville, TN – September 6, 2025  – Microvascular Therapeutics (MVT), a pioneering Utah-based biotechnology company, is honored to have...

Salt Lake City, UT – July 13, 2025  – Microvascular Therapeutics (MVT), a pioneering Utah based biotechnology company, is thrilled to...

Boston, MA – June 18, 2025 – Microvascular Therapeutics (MVT) is pleased to announce Founder and CEO, Dr. Evan Unger, as speaker on the...

May 14th, 2025 Salt Lake City, Utah: Microvascular Therapeutics, Inc. (MVT), a biotechnology company, announced that it has completed...

Tucson, AZ & Mountain View, CA – Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased...

Microvascular Therapeutics, Inc. (MVT), and SoundJet Medical, Inc. (SoundJet) announce that they have entered into a strategic...

Tucson, AZ – Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce the...

Tucson, AZ  - Dr. Evan Unger, CEO and Founder of Microvascular Therapeutics (MVT), has been awarded the 2024 Harry Fischer Award by...

Microvascular Therapeutics selected as a Participant in the 2024 Landmark Venture Forum [Tucson, AZ] – Microvascular Therapeutics Inc....

[Tucson, Arizona] – [2/05/2024] – Microvascular Therapeutics Inc. (MVT), a clinical-stage biotech company at the forefront of developing...

Microvascular Therapeutics (MVT), a clinical stage biopharma pioneering the potential of ultrasound in diagnostics and theranostics, has...

Microvascular Therapeutics, a trailblazing healthcare research and development company, announces a groundbreaking study on the treatment...